[ Price : $8.95]
Four rare disease stakeholders say they support an FDA plan to create a Rare Disease Innovation Hub and suggest its initial priori...[ Price : $8.95]
Attorney Bradley Thompson says he is surprised and disappointed that FDA is not approving enough new consensus standards to suppor...[ Price : $8.95]
Mark Cubans Cost-Plus Manufacturing and Compounding facility in Dallas, TX, receives a Form FDA-483 based on findings from a recen...[ Price : $8.95]
FDA accepts for review an Ionis Pharmaceuticals NDA for donidalorsen, an RNA-targeted treatment for preventing hereditary angioede...[ Price : $8.95]
FDA gives the green light to Phaxiam Therapeutics for a Phase 2 study (GLORIA) to evaluate its anti-Staphylococcus aureus phages i...[ Price : $8.95]
FDA approves a Journey Medical NDA for Emrosi (minocycline hydrochloride extended release capsules, 40 mg) for treating rosacea in...[ Price : $8.95]
FDA announces a pilot program designed to expedite the review of new therapies addressing unmet medical needs.[ Price : $8.95]
FDA removes the clinical holds on three CARsgen Therapeutics clinical trials evaluating CT053, CT041, and CT071.